Anticoagulant Activities of Pentosan Polysulphate (Hémoclar) Due to Release of Hepatic Triglyceride Lipase (HTGL)

Summary

Subcutaneous injections of 50 mg pentosan poly sulphate (Hemoclar) were given to normal volunteers and the effects on anti-Factor Xa activity, thrombin generation and lipase release measured. Concentrations of pentosan polysulphate were measured by a competitive binding assay and the mean peak level found to be 1.6 μg/ml. Anti-Xa clotting activity rose to 0.034 iu/ml and thrombin generation induced by lipid peroxides was inhibited by approximately 50%. Neither of these effects could be accounted for by the direct action of pentosan polysulphate at the concentrations measured. Pentosan poly sulphate was very effective in releasing lipase, approximately 70-80% of the total enzyme activity being due to hepatic triglyceride lipase (HTGL). In vitro addition of purified HTGL to plasma markedly enhanced anti-Xa clotting activity, and caused a 70% inhibition of lipid peroxide induced thrombin generation. Anti-Xa activity of postinjection plasma was increased rather than neutralised by addition of polybrene, and this effect could be mimicked by addition of polybrene to plasma containing pentosan polysulphate and purified HTGL. It is concluded that, when given in low doses subcutaneously, pentosan polysulphate acts as an indirect anticoagulant, its major effects being due to release of HTGL.

Keywords

Pentosan - Anticoagulant - Lipase

• References

• 1 Joffe S. Drug prevention of postoperative deep vein thrombosis. A comparative study of calcium heparinate and sodium pentosan polysulphate. Arch Surg 1976; 111: 37-40
• 2 Bergqvist D, Efsing HO, Hallböök T, Lindblad B. Prevention of postoperative thromboembolic complications. A prospective comparison between Dextran 70, Dihydroergotamin-Heparin and a sulphated polysaccharide. Acta Chir Scand 1980; 146: 559-568
• 3 Bergqvist D, Ljungner H. A comparative study of Dextran 70 and a sulphated polysaccharide in the prevention of postoperative thromboembolic complications. Br J Surg 1981; 68: 9-51
• 4 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulphate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980; 20: 57-68
• 5 Scully MF, Kakkar VV. Effect of a pentosan polysulphate upon thrombin and factor Xa inactivation by antithrombin III. Biochem J 1984; 222: 571-578
• 6 Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosan polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19: 455-463
• 7 Fischer A-M, Barrowcliffe TW, Thomas DP. A comparison of pentosan poly sulphate (SP54) and heparin. I: Mechanism of action on blood coagulation. Thromb Haemostas 1982; 47: 104-108
• 8 Scully MF, Kakkar VV. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54). Thromb Res 1984; 36: 187-194
• 9 MacGregor IR, Dawes J, Pepper DS, Prowse CV, Stocks J. Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides - comparison with effects upon anticoagulant activity, lipolysis and platelet a-granule proteins. Thromb Haemostas 1985; 53: 411-414
• 10 Fischer A-M, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. II: Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
• 11 Williams SP, Barrowcliffe TW. The effects of post-heparin plasma lipases on anti-Xa clotting activity. Thromb Res 1985; 37: 371-377
• 12 Gray E, Barrowcliffe TW. Anticoagulant activities of hepatic triglyceride lipase. Thromb Haemostas 1985 54. 150 (Abstr).
• 13 Barrowcliffe TW, Gray E, Kerry PJ, Gutteridge JM C. Triglyceride-rich lipoproteins are responsible for thrombin generation induced by lipid peroxides. Thromb Haemostas 1984; 52: 7-10
• 14 Gray E, Williams SP, Barrowcliffe TW. Effects of lipase enzymes on procoagulant and anticoagulant activities of lipoproteins. Biochem Soc Trans 1985; 13: 138-139
• 15 Nilsson-Ehle P, Schotz MC. A stable radioactive substrate emulsion for the assay of lipoprotein lipase. J Lipid Res 1976; 17: 536-541
• 16 Gray E, Bengtsson-Olivecrona G, Olivecrona T, Barrowcliffe TW. The anti-Xa activity of human hepatic triglyceride lipase (HTGL). J Lab Clin Med 1986 (in press)
• 17 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
• 18 Hubbard AR, Jennings CA, Barrowcliffe TW. Anticoagulant properties in vitro of heparan sulphates. Thromb Res 1984; 35: 567-576
• 19 Hubbard AR, Jennings CA. Neutralisation of heparan sulphate and low molecular weight heparin by protamine. Thromb Haemostas 1985; 53: 86-89
• 20 Fischer A-M, Dautzenberg MD, Aurousseau MH, Beguin S, Goudemand J, Hemker HC. Comparison between the effect of pentosan polysulphate, heparin and antithrombin III injections in antithrombin III deficient patients. Thromb Res 1985; 37: 295-307
• Yagi K. Assay for serum lipid peroxide level and its clinical significance. In: Lipid Peroxides in Biology and Medicine Yagi K. (ed.) 223-242 Academic Press; London: 1982
• 22 Del Maestro RF, Thaw HH, Bjork J, Planker M, Arfors K-E. Free radicals as mediators of tissue injury. Acta Physiol Scand 1980; (Suppl. 492) 43-57